keyword
MENU ▼
Read by QxMD icon Read
search

Allogeneic

keyword
https://www.readbyqxmd.com/read/29045966/-immune-effects-of-specific-ctls-response-induced-by-dendritic-cells-pulsed-with-ny-eso-1-peptide
#1
J W Liu, X Lu, Z M Yang, L J Deng, L Yang
OBJECTIVE: To explore the potential of autologous dendritic cells (DCs) pulsed with caner/testis antigen NY-ESO-1 peptides in inducing specific cytotoxic T lymphocyte (CTLs) response and antineoplastic immune function of specific CTLs. METHODS: Fifteen patients with II to III stage positive HLA -A0201(+) and NY-ESO-1(+) were enrolled in the Cancer Hospital Chinese Academy of Medical Sciences on the basis of preclinical experiments from November 2014 to October 2015, and their peripheral blood mononuclear cells (PBMCs) and peripheral blood lymphocytes (PBLs) were isolated...
October 18, 2017: Beijing da Xue Xue Bao. Yi Xue Ban, Journal of Peking University. Health Sciences
https://www.readbyqxmd.com/read/29044495/urban-particulate-matter-stimulation-of-human-dendritic-cells-enhances-priming-of-na%C3%A3-ve-cd8-t-lymphocytes
#2
Paul E Pfeffer, Tzer R Ho, Elizabeth H Mann, Frank J Kelly, Maria Sehlstedt, Jamshid Pourazar, Rosamund E Dove, Thomas Sandstrom, Ian S Mudway, Catherine M Hawrylowicz
Epidemiological studies have consistently shown associations between elevated concentrations of urban particulate matter (UPM) air pollution and exacerbations of asthma and COPD, which are both associated with viral respiratory infections. The effects of urban PM on dendritic cell (DC) stimulated CD4 T lymphocytes have been investigated previously, however little work has focused on CD8 T lymphocyte responses despite their importance in anti-viral immunity. To address this, we examined the effects of UPM on DC-stimulated naïve CD8 T cell responses...
October 16, 2017: Immunology
https://www.readbyqxmd.com/read/29043826/abo-serology-in-a-case-of-persistent-weak-a-in-a-recipient-following-a-group-o-matched-unrelated-bone-marrow-transplant
#3
Dianne E Grey, Elizabeth A Fong, Catherine Cole, Jesper Jensen, Jill Finlayson
HLA-matched hematopoietic stem cell transplantation (HSCT) from red blood cell (RBC)-incompatible donors is not uncommon. The engraftment process following ABO-incompatible allogeneic HSCT results in the transition from patient blood group to donor blood group in the recipient. In contrast, most non-hematopoietic tissues retain expression of the patient's original blood group for life, and these antigens may adsorb from the plasma onto the donor-derived RBCs. Correct serologic interpretation of the ABO blood group during this engraftment process can be difficult...
September 2017: Immunohematology
https://www.readbyqxmd.com/read/29042746/erratum-comparative-alveolar-ridge-preservation-using-allogenous-tooth-graft-versus-free-dried-bone-allograft-a-randomized-controlled-prospective-clinical-pilot-study
#4
(no author information available yet)
[This corrects the article on p. 211 in vol. 8, PMID: 28839405.].
July 2017: Contemporary Clinical Dentistry
https://www.readbyqxmd.com/read/29039818/the-role-of-b-cell-targeting-in-chronic-graft-versus-host-disease
#5
REVIEW
Ruben Rhoades, Sameh Gaballa
Chronic graft-versus-host disease (cGVHD) is a leading cause of late morbidity and mortality following allogeneic stem cell transplantation. Current therapies, including corticosteroids and calcineurin inhibitors, are only effective in roughly 50% of cases; therefore, new treatment strategies are under investigation. What was previously felt to be a T cell disease has more recently been shown to involve activation of both T and B cells, as well as a number of cytokines. With a better understanding of its pathophysiology have come more expansive preclinical and clinical trials, many focused on B cell signaling...
October 17, 2017: Biomedicines
https://www.readbyqxmd.com/read/29038460/a-novel-immunohistochemical-score-to-predict-early-mortality-in-acute-myeloid-leukemia-patients-based-on-indoleamine-2-3-dioxygenase-expression
#6
Abhishek Mangaonkar, Ashis Kumar Mondal, Sadanand Fulzule, Chetan Pundkar, Eun Jeong Park, Anand Jillella, Vamsi Kota, Hongyan Xu, Natasha M Savage, Huidong Shi, David Munn, Ravindra Kolhe
Indoleamine 2,3 dioxygenase-1 (IDO-1) is an enzyme in the kynurenine pathway which augments tumor-induced immune tolerance. Previous studies in childhood acute myeloid leukemia (AML) have shown a negative correlation of IDO-1 mRNA expression with outcomes. The aim of our study was to develop a practical and objective immunohistochemical technique to quantify IDO-1 expression on diagnostic bone marrow biopsies of AML patients in order to facilitate its use in routine clinical practice. IDO-1 mRNA was extracted from diagnostic bone marrow specimens from 29 AML patients...
October 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29038366/specifically-differentiated-t-cell-subset-promotes-tumor-immunity-over-fatal-immunity
#7
Abdulraouf Ramadan, Brad Griesenauer, Djamilatou Adom, Reuben Kapur, Helmut Hanenberg, Chen Liu, Mark H Kaplan, Sophie Paczesny
Allogeneic immune cells, particularly T cells in donor grafts, recognize and eliminate leukemic cells via graft-versus-leukemia (GVL) reactivity, and transfer of these cells is often used for high-risk hematological malignancies, including acute myeloid leukemia. Unfortunately, these cells also attack host normal tissues through the often fatal graft-versus-host disease (GVHD). Full separation of GVL activity from GVHD has yet to be achieved. Here, we show that, in mice and humans, a population of interleukin-9 (IL-9)-producing T cells activated via the ST2-IL-33 pathway (T9IL-33 cells) increases GVL while decreasing GVHD through two opposing mechanisms: protection from fatal immunity by amphiregulin expression and augmentation of antileukemic activity compared with T9, T1, and unmanipulated T cells through CD8α expression...
October 16, 2017: Journal of Experimental Medicine
https://www.readbyqxmd.com/read/29038286/allogeneic-mesenchymal-stem-cells-for-treatment-of-aki-after-cardiac-surgery
#8
Madhav Swaminathan, Mark Stafford-Smith, Glenn M Chertow, David G Warnock, Viken Paragamian, Robert M Brenner, François Lellouche, Alison Fox-Robichaud, Mohamed G Atta, Spencer Melby, Ravindra L Mehta, Ron Wald, Subodh Verma, C David Mazer
AKI after cardiac surgery remains strongly associated with mortality and lacks effective treatment or prevention. Preclinical studies suggest that cell-based interventions may influence functional recovery. We conducted a phase 2, randomized, double-blind, placebo-controlled trial in 27 centers across North America to determine the safety and efficacy of allogeneic human mesenchymal stem cells (MSCs) in reducing the time to recovery from AKI after cardiac surgery. We randomized 156 adult subjects undergoing cardiac surgery with evidence of early AKI to receive intra-aortic MSCs (AC607; n=67) or placebo (n=68)...
October 16, 2017: Journal of the American Society of Nephrology: JASN
https://www.readbyqxmd.com/read/29038036/overexpression-of-notch-ligand-delta-like-1-by-dendritic-cells-enhances-their-immunoregulatory-capacity-and-exerts-antiallergic-effects-on-th2-mediated-allergic-asthma-in-mice
#9
Chen-Chen Lee, Chu-Lun Lin, Sy-Jye Leu, Yueh-Lun Lee
Dendritic cells (DCs) are professional antigen-presenting cells, and Notch ligand Delta-like-1 (DLL1) on DCs was implicated in type 1T helper (Th1) differentiation. In this study, we produced genetically engineered bone marrow-derived DCs that expressed DLL1 (DLL1-DCs) by adenoviral transduction. DLL1-DCs exerted a fully mature phenotype, and had positive effects on expression levels of interleukin (IL)-12 and costimulatory molecules. Coculture of allogeneic T cells with ovalbumin (OVA)-pulsed DLL1-DCs enhanced T cell proliferative responses and promoted Th1 cell differentiation...
October 13, 2017: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/29037890/double-expressor-lymphoma-is-associated-with-poor-outcomes-after-allogeneic-hematopoietic-cell-transplantation
#10
Ichiro Kawashima, Yoshihiro Inamoto, Akiko Miyagi Maeshima, Junko Nomoto, Kinuko Tajima, Tadahiro Honda, Takafumi Shichijo, Akihisa Kawajiri, Tomonari Takemura, Akio Onishi, Ayumu Ito, Takashi Tanaka, Shigeo Fuji, Saiko Kurosawa, Sung-Won Kim, Dai Maruyama, Kensei Tobinai, Yukio Kobayashi, Takahiro Fukuda
Double-expressor lymphoma is a diffuse large B-cell lymphoma that exhibits co-expression of MYC and BCL2 proteins by immunohistochemistry. Patients with double-expressor lymphoma have a poor prognosis after standard chemoimmunotherapy or after high-dose chemotherapy with autologous transplantation, but the prognostic impact of double-expressor lymphoma after allogeneic hematopoietic cell transplantation has not been well determined. We retrospectively analyzed 60 consecutive patients with de novo diffuse large B-cell lymphoma or transformed follicular lymphoma who underwent allogeneic transplantation at our center and whose immunohistochemistry results were available...
October 13, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29037354/baseline-factors-affecting-closure-of-venous-leg-ulcers
#11
William A Marston, William J Ennis, John C Lantis, Robert S Kirsner, Robert D Galiano, Wolfgang Vanscheidt, Sabine A Eming, Marcin Malka, D Innes Cargill, Jaime E Dickerson, Herbert B Slade
OBJECTIVE: The objective of this study was to characterize factors associated with closure of venous leg ulcers (VLUs) in a pooled analysis of subjects from three randomized clinical trials. METHODS: Closure of VLUs after treatment with HP802-247, an allogeneic living cell therapy consisting of growth-arrested human keratinocytes and fibroblasts, vs standard therapy with compression bandaging was evaluated in three phase 3 clinical trials of similar design. Two trials enrolled subjects with VLUs ranging from 2 cm(2) to 12 cm(2) in area with 12-week treatment periods; the third trial enrolled subjects with VLUs between >12 cm(2) and ≤36 cm(2) with a 16-week treatment period...
November 2017: Journal of Vascular Surgery. Venous and Lymphatic Disorders
https://www.readbyqxmd.com/read/29037020/factors-associated-with-pulmonary-toxicity-after-myeloablative-conditioning-using-fractionated-total-body-irradiation
#12
Hwa Kyung Byun, Hong In Yoon, Jaeho Cho, Hyun Ju Kim, Yoo Hong Min, Chuhl Joo Lyu, June-Won Cheong, Jin Seok Kim, Hyo Sun Kim, Soo-Jeong Kim, Andrew Jihoon Yang, Byung Min Lee, Won Hee Lee, Joongyo Lee, Ki Jung Ahn, Chang-Ok Suh
PURPOSE: Pulmonary toxicities, including infectious pneumonia (IP) and idiopathic pneumonia syndrome (IPS), are serious side effects of total body irradiation (TBI) used for myeloablative conditioning. This study aimed to evaluate clinical factors associated with IP and IPS following TBI. MATERIALS AND METHODS: Fifty-eight patients with hematologic malignancies who underwent TBI before allogeneic hematopoietic stem cell transplantation between 2005 and 2014 were reviewed...
September 2017: Radiation Oncology Journal
https://www.readbyqxmd.com/read/29035589/the-activity-of-nintedanib-in-an-animal-model-of-allogenic-left-lung-transplantation-resembling-aspects-of-allograft-rejection
#13
Marietta von Suesskind-Schwendi, Elke Boxhammer, Stephan W Hirt, Stephan Schreml, Christof Schmid, Lutz Wollin, Karla Lehle
AIM OF THE STUDY: The prevention and treatment of chronic lung allograft dysfunction (CLAD) after lung transplantation (LTx) remain unsatisfactory. Growth factors may play an important role in the development of CLAD. This study evaluated the effects of nintedanib, a receptor tyrosine kinase inhibitor, in the treatment of CLAD after experimental LTx. MATERIALS AND METHODS: A rat model of left lung allo-transplantation (Fisher 344 to Wistar Kyoto) was used to evaluate the effect of nintedanib (50 mg/kg per day) on the development of CLAD...
October 16, 2017: Experimental Lung Research
https://www.readbyqxmd.com/read/29035398/risks-factors-and-timing-of-genital-human-papillomavirus-hpv-infection-in-female-stem-cell-transplant-survivors-a-longitudinal-study
#14
D Shanis, P Anandi, C Grant, A Bachi, N Vyas, M A Merideth, P A Pophali, E Koklanaris, S Ito, B N Savani, A J Barrett, M Battiwalla, P Stratton
This longitudinal single-center study describes the timing and risk factors for genital human papillomavirus (HPV) disease in women after allogeneic hematopoietic cell transplantation (HCT). Between 1994 and 2014, 109 females underwent HCT of whom 82 surviving transplant for >1 year had regular, comprehensive genital tract assessment and treatment of HPV disease. The cumulative proportions of any genital HPV infection at 1, 3, 5, 10 and 20 years were 4.8%, 14.9%, 28.1%, 36.7% and 40.9%, respectively. Demographic, disease-related factors, chronic GvHD (cGvHD) and its treatment were analyzed for their association with persistent, multifocal or severe genital HPV disease...
October 16, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29035392/long-term-outcome-of-mixed-chimerism-after-stem-cell-transplantation-for-thalassemia-major-conditioned-with-busulfan-and-cyclophosphamide
#15
N A Fouzia, E S Edison, K M Lakshmi, A Korula, S R Velayudhan, P Balasubramanian, A Abraham, A Viswabandya, B George, V Mathews, A Srivastava
Mixed chimerism (MC) occurs frequently after allogeneic hematopoietic stem cell transplantation (HSCT) for thalassemia major (TM) and may be associated with rejection. We report the outcome of MC in 132 TM patients conditioned with Busulphan/Cyclophosphamide, who had successful engraftment and had ⩾1 year follow-up. Chimerism was first assessed at day +28, then every 3-9 months or more frequently if there was MC. If rejection was suspected, immunosuppression was stopped and donor-lymphocyte infusion (DLI) was given if there was no response...
October 16, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29033451/dasatinib-and-azacitidine-followed-by-haploidentical-stem-cell-transplant-for-chronic-myeloid-leukemia-with-evolving-myelodysplasia-a-case-report-and-review-of-treatment-options
#16
Fabian Lang, Lydia Wunderle, Heike Pfeifer, Susanne Schnittger, Gesine Bug, Oliver G Ottmann
BACKGROUND CML presenting with a variant Philadelphia translocation, atypical BCR-ABL transcript, additional chromosomal aberrations, and evolving MDS is uncommon and therapeutically challenging. The prognostic significance of these genetic findings is uncertain, even as singular aberrations, with nearly no data on management and outcome when they coexist. MDS evolving during the course of CML may be either treatment-associated or an independently coexisting disease, and is generally considered to have an inferior prognosis...
October 16, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/29033080/reconstitution-of-th17-tc17-and-treg-cells-after-paediatric-haematopoietic-stem-cell-transplantation-impact-of-interleukin-7
#17
Katrine Kielsen, Lars P Ryder, David Lennox-Hvenekilde, Monika Gad, Claus H Nielsen, Carsten Heilmann, Marianne Ifversen, Anders Elm Pedersen, Klaus Müller
Successful reconstitution of T lymphocytes after allogeneic haematopoietic stem cell transplantation (HSCT) is needed to establish the graft-versus-leukaemia effect and an effective anti-microbial defense, but the ratio between functionally different T-cell subsets needs to be balanced to avoid graft-versus-host disease (GVHD). IL-7 is essential for T-cell generation in the thymus and peripheral T-cell homeostasis. High IL-7 levels have been associated with impaired T-cell reconstitution, increased risk of acute GVHD and treatment-related mortality, but the underlying cellular mechanisms behind these associations have not been investigated previously...
October 9, 2017: Immunobiology
https://www.readbyqxmd.com/read/29032736/coccidioidomycosis-immunoglobulin-deficiency-safety-challenges-with-car-t-cells-therapy-for-relapsed-lymphoma
#18
Umar Zahid, Al-Aman Shaukat, Nida Hassan, Faiz Anwer
Treatment of patients with relapsed or refractory lymphoma may require allogenic hematopoietic stem cell transplant (HSCT), but treatment of post-transplant relapse disease remains very challenging. Donor lymphocyte infusion and blinatumomab have been used with limited success for the treatment of relapse. Initial data on donor-derived CAR T cells has shown this modality to be safe and highly effective in various hematological malignancies. We present a case of a patient with highly refractory, transformed follicular lymphoma who failed both autologous and allogenic HSCT...
October 2017: Immunotherapy
https://www.readbyqxmd.com/read/29032733/car-t-cells-and-allogeneic-hematopoietic-stem-cell-transplantation-for-relapsed-refractory-b-cell-acute-lymphoblastic-leukemia
#19
Jun Liu, Xi Zhang, Jiang F Zhong, Cheng Zhang
Relapsed/refractory acute lymphoblastic leukemia (ALL) has a low remission rate after chemotherapy, a high relapse rate and poor long-term survival even when allogeneic hematopoietic stem cell transplantation (allo-HSCT) is performed. Chimeric antigen receptors redirected T cells (CAR-T cells) can enhance disease remission with a favorable outcome for relapsed/refractory ALL, though some cases quickly relapsed after CAR-T cell treatment. Thus, treatment with CAR-T cells followed by allo-HSCT may be the best way to treat relapsed/refractory ALL...
October 2017: Immunotherapy
https://www.readbyqxmd.com/read/29032731/cytogenetic-risk-stratification-may-predict-allogeneic-hematopoietic-stem-cell-transplantation-outcomes-for-chronic-myelomonocytic-leukemia
#20
Kenji Motohashi, Shin Fujisawa, Noriko Doki, Takeshi Kobayashi, Takehiko Mori, Kensuke Usuki, Masatsugu Tanaka, Shinichiro Fujiwara, Shinichi Kako, Yasuyuki Aoyama, Masahiro Onoda, Shingo Yano, Moritaka Gotoh, Heiwa Kanamori, Satoshi Takahashi, Shinichiro Okamoto
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for chronic myelomonocytic leukemia (CMML); however, factors predicting allo-HSCT outcomes for CMML have not been well defined. This study assessed whether the existing five scoring systems for CMML prognosis could be applied for predicting allo-HSCT outcomes. We retrospectively evaluated 38 patients who underwent allo-HSCT for CMML from 2000 to 2014. At 3 years, overall survival (OS) and disease-free survival were 34...
October 16, 2017: Leukemia & Lymphoma
keyword
keyword
9611
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"